The first patient has been enrolled in Rox Medical's CONTROL-HTN international randomised, controlled trial of the Rox Flow procedure for the treatment of resistant hypertension. The first patient was enrolled at UZ Brussel Hospital, Belgium, by Professor Danny Schoors and Dr Sofie Brouwers. Schoors performed the procedure in the cardiac catheterisation laboratory in under one hour.
The Rox Flow procedure is a minimally-invasive catheter procedure to place a small coupler between the artery and vein in the upper leg. The procedure reduces peripheral vascular resistance, thereby achieving a long-term reduction in hypertension. Additionally, the Flow procedure only involves the vascular structure, has an immediate effect and is fully reversible. The procedure is not approved for use in the US.